9h
Stockhead on MSNHealth Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agentBrazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...
Melbourne-based biotech Telix Pharmaceuticals has announced that its prostate cancer diagnostic agent Illuccix has been ...
In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
4d
Pharmaceutical Technology on MSNTelix’s new lead-212 generator could dispel medical isotope scalability hurdlesLead-212 is a promising radioactive isotope for use in targeted alpha therapy, an alternative modality to beta-particle-based ...
TLX opened at $17.30 on Friday. The firm’s fifty day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 52-week low of $14.01 and a 52-week high of $30.36.
The high-flying S&P/ASX 200 Index (ASX: XJO) share made a major acquisition announcement. Here’s what you need to know.
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results